Cited by 1,463Lipoproteins and Cardiovascular HealthPharmacovigilance and Adverse Drug ReactionsMuscle and Compartmental Disorders

The DOI matches its Crossref record; 103 of the 114 references it cites were found in a registry or an index.

Statin-Associated Myopathy

Thompson, Paul D., Clarkson, Priscilla, Karas, Richard H.·2003·JAMA

DOI 10.1001/jama.289.13.1681

Open this paper in CoChat — free account

Abstract

Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are associated with skeletal muscle complaints, including clinically important myositis and rhabdomyolysis, mild serum creatine kinase (CK) elevations, myalgia with and without elevated CK levels, muscle weakness, muscle cramps, and persistent myalgia and CK elevations after statin withdrawal. We performed a literature review to provide a clinical summary of statin-associated myopathy and discuss possible mediating mechanisms. We also update the US Food and Drug Administration (FDA) reports on statin-associated rhabdomyolysis. Articles on statin myopathy were identified via a PubMed search through November 2002 and articles on statin clinical trials, case series, and review articles were identified via a PubMed search through January 2003. Adverse event reports of statin-associated rhabdomyolysis were also collected from the FDA MEDWATCH database. The literature review found that reports of muscle problems during statin clinical trials are extremely rare. The FDA MEDWATCH Reporting System lists 3339 cases of statin-associated rhabdomyolysis reported between January 1, 1990, and March 31, 2002. Cerivastatin was the most commonly implicated statin. Few data are available regarding the frequency of less-serious events such as muscle pain and weakness, which may affect 1% to 5% of patients. The risk of rhabdomyolysis and other adverse effects with statin use can be exacerbated by several factors, including compromised hepatic and renal function, hypothyroidism, diabetes, and concomitant medications. Medications such as the fibrate gemfibrozil alter statin metabolism and increase statin plasma concentration. How statins injure skeletal muscle is not clear, although recent evidence suggests that statins reduce the production of small regulatory proteins that are important for myocyte maintenance.

Integrity signals

Registry

Crossref · 10.1001/jama.289.13.1681

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,638
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Pedersen, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,098
Physicians Desk Reference
Arky, R. A. (1994) · Cited by 2,632
Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes<SUBTITLE>The MIRACL Study: A Randomized Controlled Trial</SUBTITLE>
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
PROTEIN PRENYLATION: Molecular Mechanisms and Functional Consequences
Zhang, F. L., & Casey, P. J. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.001325 · Cited by 2,018
Effect of Statin Therapy on C-Reactive Protein Levels
Albert, M. A., Danielson, E., Rifai, N., Ridker, P. M., & for the PRINCE Investigators (2001) · JAMA · doi:10.1001/jama.286.1.64 · Cited by 1,644
Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research; Group, T. A. O. A. C. F. T. A. C. R. G. (2002) · JAMA · doi:10.1001/jama.288.23.2998 · Cited by 1,328
An Essential Role for Rho, Rac, and Cdc42 GTPases in Cell Cycle Progression Through G 1
Olson, M. F., Ashworth, A., & Hall, A. (1995) · Science · doi:10.1126/science.7652575 · Cited by 1,148
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Writing Committee Members:, Pasternak, R. C., Smith, S. C., Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., & Lenfant, C. (2002) · Circulation · doi:10.1161/01.cir.0000032466.44170.44 · Cited by 1,088
The Effect of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation on Obstructive Changes in Saphenous-Vein Coronary-Artery Bypass Grafts
The Post Coronary Artery Bypass Graft Trial Investigators (1997) · New England Journal of Medicine · doi:10.1056/nejm199701163360301 · Cited by 969
Aggressive Lipid-Lowering Therapy Compared with Angioplasty in Stable Coronary Artery Disease
Pitt, B., Waters, D. D., Brown, W. V., Boven, A. J. V., Schwartz, L., Title, L. M., Eisenberg, D., Shurzinske, L., & McCormick, L. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907083410202 · Cited by 939
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Jukema, J., Bruschke, A. V., van Boven, A. J., Reiber, J., Bal, E., Zwinderman, A., Jansen, H., Boerma, G., van Rappard, F. M., & Kong, L. I. (1995) · Circulation · doi:10.1161/01.cir.91.10.2528 · Cited by 911
A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2)
Hsiang, B. C., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V. G., Yang, W.-P., & Kirchgessner, T. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37161 · Cited by 638
Cerivastatin and Reports of Fatal Rhabdomyolysis
Staffa, J. A., Chang, J. T., & Green, L. (2002) · New England Journal of Medicine · doi:10.1056/nejm200202143460721 · Cited by 627
Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II)
Crouse, J. R., Byington, R. P., Bond, M. G., Espefand, M. A., Craven, T. E., Sprinkle, J. W., McGovern, M. E., & Furberg, C. D. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80580-3 · Cited by 607
Statin-associated myopathy with normal creatine kinase levels
Phillips, P. S., Haas, R. H., Bannykh, S., Hathaway, S., Gray, N. L., Kimura, B. J., Vladutiu, G. D., England, J. D. F., & and the Scripps Mercy Clinical Research Center* (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-7-200210010-00009 · Cited by 565
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
Davidson, M. H., Mcgarry, T. F., Bettis, R. B., Melani, L., Lipka, L., LeBeaut, A., Suresh, R., Sun, S. H., & Veltri, E. P. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02610-4 · Cited by 557
Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention
Athyros, V. G., Papageorgiou, A. A., Mercouris, B. R., Athyrou, V. V., Symeonidis, A. N., Basayannis, E. O., Demitriadis, D. S., & Kontopoulos, A. G. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125000787 · Cited by 533
Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
Waters, D., Higginson, L., Gladstone, P., Kimball, B., May, M. L. L., Boccuzzi, S., & Lésperance, J. (1994) · Circulation · doi:10.1161/01.cir.89.3.959 · Cited by 512
ACC/AHA/NHLBI clinical advisory on the use and safety of statins11When citing this document, the American College of Cardiology, American Heart Association, and National Heart, Lung and Blood Institute would appreciate the following citation format: Pasternak RC, Smith SC, Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Advisory on the Use and Safety of Statins. J Am Coll Cardiol 2002;40:568–73.22This document is available on the Web sites of the ACC (www.acc.org), the AHA (www.americanheart.org), and the NHLBI (www.nhlbi.nih.gov/guidelines/cholesterol).
Pasternak, R. C., Smith, S. C., Merz, C. N. B., Grundy, S. M., Cleeman, J. I., & Lenfant, C. J. M. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02030-2 · Cited by 507
Tissue distribution of the multidrug resistance protein.
Flens, M. J., Zaman, G. J., van der Valk, P., Izquierdo, M. A., Schroeijers, A. B., Scheffer, G. L., van der Groep, P., de Haas, M., Meijer, C. J. L. M., & Scheper, R. J. (1996) · Europe PMC (PubMed Central) · Cited by 473
Simvastatin Reduces Graft Vessel Disease and Mortality After Heart Transplantation: A Four-Year Randomized Trial
Wenke, K., Meiser, B., Thiery, J., Nagel, D., von Scheidt, W., Steinbeck, G., Seidel, D., & Reichart, B. (1997) · Circulation · doi:10.1161/01.cir.96.5.1398 · Cited by 444
Myopathy and Rhabdomyolysis Associated With Lovastatin-Gemfibrozil Combination Therapy
Pierce, L. R. (1990) · JAMA · doi:10.1001/jama.1990.03450010075034 · Cited by 425
Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events
Pitt, B., Mancini, G. B. J., Ellis, S. G., Rosman, H., Park, J.-S., & Mcgovern, M. E. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00301-0 · Cited by 424
3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Isoprenylation Inhibitors Induce Apoptosis of Vascular Smooth Muscle Cells in Culture
Guijarro, C., Blanco‐Colio, L. M., Ortego, M., Alonso, C., Ortíz, A., Plaza, J. J. G., Dı́az-Jullien, C., Hernández, G., & Egido, J. (1998) · Circulation Research · doi:10.1161/01.res.83.5.490 · Cited by 390
Use of Intravascular Ultrasound to Compare Effects of Different Strategies of Lipid-Lowering Therapy on Plaque Volume and Composition in Patients With Coronary Artery Disease
Schartl, M., Bocksch, W., Koschyk, D. H., Voelker, W., Karsch, K. R., Kreuzer, J., Hausmann, D., Beckmann, S., Gross, M. C., & for the German Atorvastatin Intravascular Ultrasound Study Investigators (GAIN) (2001) · Circulation · doi:10.1161/hc2901.093188 · Cited by 364
Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency
Rötig, A., Appelkvist, E., Géromel, V., Chrétien, D., Kadhom, N., Edery, P., Bideau, M. L., Dallner, G., Münnich, A., Ernster, L., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02531-9 · Cited by 354
Physicians Desk Reference
Standing, O. (2002) · Cited by 351
Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
Prueksaritanont, T., Subramanian, R., Fang, X., Ma, B., Qiu, Y., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.5.505 · Cited by 344
Efficacy and long-term adverse effect pattern of lovastatin
Tobert, J. A. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)90004-5 · Cited by 335
Evidence of Plasma CoQ10‐Lowering Effect by HMG‐CoA Reductase Inhibitors: A Double‐Blind, Placebo‐Controlled Study
Ghirlanda, G., Oradei, A., Manto, A., Lippa, S., Uccioli, L., Caputo, S., Greco, A. V., & Littarru, G. P. (1993) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1993.tb03948.x · Cited by 324
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
Prueksaritanont, T., Tang, C., Qiu, Y., Mu, L., Subramanian, R., & Lin, J. H. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.11.1280 · Cited by 322
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Effects of Fluvastatin on Coronary Atherosclerosis in Patients With Mild to Moderate Cholesterol Elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])
Herd, J. A., Ballantyne, C. M., Farmer, J. A., Ferguson, J. J., Jones, P. H., West, M. S., Gould, K. L., & Gotto, A. M. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00346-9 · Cited by 315
Drug–Grapefruit Juice Interactions
Kane, G. C., & Lipsky, J. J. (2000) · Mayo Clinic Proceedings · doi:10.4065/75.9.933 · Cited by 303
Rhabdomyolysis in Patients Receiving Lovastatin after Cardiac Transplantation
East, C., Alivizatos, P. A., Grundy, S. M., Jones, P. H., & Farmer, J. A. (1988) · New England Journal of Medicine · doi:10.1056/nejm198801073180111 · Cited by 291
Mechanistic Studies on Metabolic Interactions between Gemfibrozil and Statins
Prueksaritanont, T., Zhao, J. J., Ma, B., Roadcap, B. A., Tang, C., Qiu, Y., Liu, L., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1042 · Cited by 282
Effects of Cyclosporine Therapy on Plasma Lipoprotein Levels
Ballantyne, C. M. (1989) · JAMA · doi:10.1001/jama.1989.03430010065032 · Cited by 281
HMG-CoA Reductase Inhibitors and Myotoxicity
Ucar, M., Mjörndal, T., & Dahlqvist, R. (2000) · Drug Safety · doi:10.2165/00002018-200022060-00003 · Cited by 279
Lipid‐lowering drugs and mitochondrial function: effects of HMG‐CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio
DE PINIEUX, G., CHARIOT, P., AMMI‐SAÏD, M., LOUARN, F., LEJONC, J. L., ASTIER, A., JACOTOT, B., & GHERARDI, R. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.04178.x · Cited by 262
A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty Final results of the fluvastatin angiographic restenosis (FLARE) trial
Serruys, P. W. J. C. (1999) · European Heart Journal · doi:10.1053/euhj.1998.1150 · Cited by 258
Myolysis and Acute Renal Failure in a Heart-Transplant Recipient Receiving Lovastatin
Norman, D. J., Illingworth, D. R., Munson, J. L., & Hosenpud, J. D. (1988) · New England Journal of Medicine · doi:10.1056/nejm198801073180110 · Cited by 255
Rho GTPase signalling pathways in the morphological changes associated with apoptosis
Coleman, M. L., & Olson, M. F. (2002) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400987 · Cited by 250
An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia
Durrington, P. N. (2001) · Heart · doi:10.1136/heart.85.5.544 · Cited by 243
Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia
Sawayama, Y., Shimizu, C., Maeda, N., Tatsukawa, M., Kinukawa, N., Koyanagi, S., Kashiwagi, S., & Hayashi, J. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01783-1 · Cited by 226
Acute Muscular Syndrome Associated with Administration of Clofibrate
Langer, T., & Levy, R. I. (1968) · New England Journal of Medicine · doi:10.1056/nejm196810172791604 · Cited by 189
Lovastatin increases exercise-induced skeletal muscle injury
Thompson, P. D., Zmuda, J. M., Domalik, L. J., Zimet, R., Staggers, J. E., & Guyton, J. R. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90218-3 · Cited by 177
Self-citation
Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans
Laaksonen, R., Jokelainen, K., Sahi, T., Tikkanen, M. J., & Himberg, J.-J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90266-x · Cited by 177
The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle
Laaksonen, R., Jokelainen, K., Laakso, J., Sahi, T., Härkönen, M., Tikkanen, M. J., & Himberg, J.-J. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89180-1 · Cited by 171
The Efficacy and Six-Week Tolerability of Simvastatin 80 and 160 mg/Day
Davidson, M., Stein, E. A., Dujovne, C. A., Hunninghake, D. B., Weiss, S. R., Knopp, R. H., Illingworth, D. R., Mitchel, Y., Melino, M. R., Zupkis, R. V., et al. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00742-4 · Cited by 167
Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses*
Olbricht, C. J., Wanner, C., Eisenhauer, T., Kliem, V., Doll, R., Boddaert, M., O'Grady, P., Krekler, M., Mangold, B., & Christians, U. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90034-5 · Cited by 165
Reduction of Transient Myocardial Ischemia With Pravastatin in Addition to the Conventional Treatment in Patients With Angina Pectoris
Boven, A. J. V., Jukema, J. W., Zwinderman, A. H., Crijns, H. J. G. M., Lie, K. I., & Bruschke, A. V. G. (1996) · Circulation · doi:10.1161/01.cir.94.7.1503 · Cited by 163
Beneficial effects of pravastatin (±colestyramine/niacin) initiated immediately after a coronary event (the randomized lipid-coronary artery disease [L-CAD] study)
Arntz, H.-R., Agrawal, R., Wunderlich, W., Schnitzer, L., Stern, R., Fischer, F., & Schultheiß, H. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01230-3 · Cited by 158
Effect of Nifedipine and Cerivastatin on Coronary Endothelial Function in Patients With Coronary Artery Disease
The ENCORE Investigators (2003) · Circulation · doi:10.1161/01.cir.0000046488.52939.bf · Cited by 153
Ras family genes: An interesting link between cell cycle and cancer
Macaluso, M., Russo, G. L., Cinti, C., Bazan, V., Gebbia, V., & Russo, A. D. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10109 · Cited by 145
Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter.
Yamazaki, M., Akiyama, S., Ni'inuma, K., Nishigaki, R., & Sugiyama, Y. (1997) · PubMed · doi:10.7270/q2cr5vmx · Cited by 140
Effect of Pravastatin on Angiographic Restenosis After Coronary Balloon Angioplasty fn1fn1This study was supported by a grant from Bristol Myers Squibb Laboratories, Paris.
Bertrand, M. E., McFadden, E. P., Fruchart, J., BELLE, E. V., Commeau, P., Grollier, G., Bassand, J., Machecourt, J., Cassagnes, J., Mossard, J.-M., et al. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00259-3 · Cited by 135
Catastrophic medical events with exhaustive exercise: “White collar rhabdomyolysis”
Knöchel, J. P. (1990) · Kidney International · doi:10.1038/ki.1990.263 · Cited by 134
Inhibition of Cholesterol Synthesis by Squalene Synthase Inhibitors Does Not Induce Myotoxicityin Vitro
Flint, O. P., Masters, B. A., Gregg, R. E., & Durham, S. K. (1997) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1997.8131 · Cited by 132
Long-term risk stratification for survivors of acute coronary syndromes
Marschner, I. C., Colquhoun, D. M., Simes, R. J., Glasziou, P., Harris, P., Singh, B., Friedlander, D. H., White, H. D., Thompson, P., & Tonkin, A. M. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01360-2 · Cited by 128
Self-citation
Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE)
Sacks, F. M., Pfeffer, M. A., Moyé, L. A., Brown, L. E., Hamm, P., Cole, T. G., HAWKINS, C. M., D, E. B. M., & The CARE Investigators (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90276-q · Cited by 125
Long-term Safety of Hepatic Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitors
Bottorff, M. B., & Hansten, P. D. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.15.2273 · Cited by 123
Effects of concentric and eccentric contractions on phosphorylation of MAPKerk1/2 and MAPKp38 in isolated rat skeletal muscle
Wretman, C., Lionikas, A., Widegren, U., Lännergren, J., Westerblad, H., & Henriksson, J. (2001) · The Journal of Physiology · doi:10.1111/j.1469-7793.2001.00155.x · Cited by 122
The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment
Riegger, G. A. J. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00062-3 · Cited by 118
Influence of exercise intensity on ERK/MAP kinase signalling in human skeletal muscle
Widegren, U., Wretman, C., Lionikas, A., Hedin, G., & Henriksson, J. (2000) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s004240000417 · Cited by 118
Long-term safety and efficacy profile of simvastatin
Boccuzzi, S. J., Bocanegra, T. S., Walker, J. F., Shapiro, D. R., & Keegan, M. E. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90182-k · Cited by 116
Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial
Holdaas, H., Jardine, A. G., Wheeler, D. C., Brekke, I. B., Conlon, P. J., Fellström, B., Hammad, A., Holme, I., Isoniemi, H., Moore, R. H., et al. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00010.x · Cited by 110
The effect of simvastatin on progression of coronary artery disease: The Multicenter Coronary Intervention Study (CIS)
Bestehorn, H.-P., Rensing, U. F. E., Roskamm, H., Betz, P., Benesch, L., Schemeitat, K., Blümchen, G., Claus, J., Mathes, P., KAPPENBERGER, L. J., et al. (1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015224 · Cited by 99
Safety considerations for statins
Bolego, C., Baetta, R., Bellosta, S., Corsini, A., & Paoletti, R. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200212000-00007 · Cited by 98
Simvastatin-induced rhabdomyolysis followed by a melas syndrome
Chariot, P., Abadia, R., Agnus, D., Danan, C., Charpentier, C., & Gherasdi, R. K. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90129-d · Cited by 95
Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death
Knapp, A. C., Huang, J., Starling, G. C., & Kiener, P. A. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00462-1 · Cited by 95
Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors
Laaksonen, R., Ojala, J.-P., Tikkanen, M. J., & Himberg, J. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00194398 · Cited by 94
Withdrawal of Posicor From Market
SoRelle, R. (1998) · Circulation · doi:10.1161/01.cir.98.9.831 · Cited by 90
Statin myopathies: pathophysiologic and clinical perspectives.
Baker, S. K., & Tarnopolsky, M. A. (2001) · PubMed · Cited by 90
Drug interactions and the statins.
Herman, R. J. (1999) · Europe PMC (PubMed Central) · Cited by 86
Cholestasis and Regulation of Genes Related to Drug Metabolism and Biliary Transport in Rat Liver Following Treatment with Cyclosporine A and Sirolimus (Rapamycin)
Bramow, S., Ott, P., Nielsen, F. T., Bangert, K., Tygstrup, N., & Dalhoff, K. (2001) · Pharmacology & Toxicology · doi:10.1034/j.1600-0773.2001.d01-147.x · Cited by 75
Evaluation and management of dyslipidemia in patients with HIV infection
Green, M. L. (2002) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2002.20201.x · Cited by 68
LOVASTATIN, ISOPRENES, AND MYOPATHY
Walravens, P., Greene, C. L., & Frerman, F. E. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91108-2 · Cited by 66
Exercise and diet reduce risk of diabetes, US study shows
Charatan, F. (2001) · BMJ · doi:10.1136/bmj.323.7309.359 · Cited by 62
The role of cholesterol‐lowering agents in drug‐induced rhabdomyolysis and polymyositis
Goldman, J. A., Fishman, A. B., Lee, J. E., & Johnson, R. J. (1989) · Arthritis & Rheumatism · doi:10.1002/anr.1780320324 · Cited by 61
Rhabdomyolysis and Simvastatin
Deslypère, J. P., & Vermeulen, A. T. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-4-342_1 · Cited by 57
Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts
Matzno, S., Yamauchi, T., Gohda, M., Ishida, N., Katsuura, K., Hanasaki, Y., Tokunaga, T., Itoh, H., & Nakamura, N. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37182-0 · Cited by 50
Clofibrate-Induced Muscle Damage with Myoglobinuria and Cardiomyopathy
Smals, A. G., Beex, L. V. A. M., & KLOPPENBORG, P. W. C. (1977) · New England Journal of Medicine · doi:10.1056/nejm197704212961617 · Cited by 46
Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies With Familial Hypercholesterolemia [ExPRESS fh])
Nolting, P. R. W. D. S., Buirma, R. J. A., Hutten, B. A., & Kastelein, J. J. P. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02449-9 · Cited by 41
Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
Rationale, Design, and Baseline Characteristics of a Trial Comparing Aggressive Lipid Lowering With Atorvastatin Versus Revascularization Treatments (AVERT) fn1fn1This work is supported by a grant from Parke-Davis Pharmaceutical Research, a Division of Warner-Lambert Company, Ann Arbor, Michigan.
McCormick, L. S., Black, D. M., Waters, D. D., Brown, W. V., & Pitt, B. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00627-9 · Cited by 38
Increases in Creatine Kinase After Exercise in Patients Treated With HMG Co-A Reductase Inhibitors
Thompson, P. D., Nugent, A. M., & Herbert, P. N. (1990) · JAMA · doi:10.1001/jama.1990.03450230024013 · Cited by 37
Self-citation
Cytochrome P450 drug interactions: are they clinically relevant?
Martin, J., & Fay, M. F. (2001) · Australian Prescriber · doi:10.18773/austprescr.2001.007 · Cited by 35
Niacin-induced myopathy
Gharavi, A. G., Diamond, J. A., Smith, D. A., & Phillips, R. A. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90453-7 · Cited by 35
Intraoperative Rhabdomyolysis in a Patient Receiving Pravastatin, a 3-Hydroxy-3-methylglutaryl Coenzyme A (HMG CoA) Reductase Inhibitor
Rosenberg, A. D., Neuwirth, M. G., Kagen, L. J., Singh, K., Fischer, H. D., & Bernstein, R. L. (1995) · Anesthesia & Analgesia · doi:10.1097/00000539-199511000-00034 · Cited by 23
Rhabdomyolysis due to combined treatment with lovastatin and cholestyramine.
Chrysanthopoulos, C. J., & Kounis, N. G. (1992) · BMJ · doi:10.1136/bmj.304.6836.1225 · Cited by 15
Intraoperative Rhabdomyolysis in a Patient Receiving Pravastatin, a 3-Hydroxy-3-methylglutaryl Coenzyme A (HMG CoA) Reductase Inhibitor
Rosenberg, A. D., Neuwirth, M. G., Kagen, L. J., et al. (1995) · Anesthesia & Analgesia · doi:10.1213/00000539-199511000-00034 · Cited by 8

Research works printed but not linked: 9

Fuhrmans, 2002, Bayer discloses higher death toll from Baycol., Wall Street Journal, A10
Hamilton-Craig, 2001, Statin-associated myopathy., Med J Aust, 175, 486, 10.5694/mja2.2001.175.issue-9 · DOI
Omar, 2002, FDA adverse event reports on statin-associated rhabdomyolysis., Ann Pharmacother, 36, 288, 10.1345/aph.1A289 · DOI · Paper page
GISSI Prevenzione Investigators, 2000, Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico)?, Ital Heart J, 1, 810
Omar, 2001, Rhabdomyolysis and HMG-CoA reductase inhibitors., Ann Pharmacother, 35, 1096, 10.1345/aph.10228 · DOI · Paper page
Shek, 2001, Statin-fibrate combination therapy., Ann Pharmacother, 35, 908, 10.1345/aph.10315 · DOI · Paper page
Prueksaritanont, 2002, Metabolic interactions between gemfibrozil and statins in human liver preparations [abstract]., Circulation, 106, II185
Not Available, 2001, Cardiovascular Trials Review
Not Available, 2002, Cardiovascular Trials Review

Sorted by citations

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study
Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226
Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update
Schächter, M. (2004) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00299.x · Cited by 1,247
Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians.
Huerta-Alardin, A. L., Varón, J., & Marik, P. E. (2004) · Critical Care · doi:10.1186/cc2978 · Cited by 910

See all 1,463

Authors: Thompson, P. D., Clarkson, P., & Karas, R. H.
Affiliations: Hartford Hospital (US)
ORCID: Thompson, Paul D.
Karas, Richard H.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2003-04-02
Volume: 289
Issue: 13
Pages: 1681
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.289.13.1681
OpenAlex: W2059078444
Cited by: 1,463
References: 114
Citations by year: 2026: 8 · 2025: 22 · 2024: 31 · 2023: 27 · 2022: 30 · 2021: 33 · 2020: 38 · 2019: 54 · 2018: 52 · 2017: 54 · 2016: 79 · 2015: 60 · 2014: 76 · 2013: 75 · 2012: 97
FWCI: 19.53
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
ScholarWorks@UMassAmherst (University of Massachusetts Amherst) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Health Sciences › Medicine › Surgery › Muscle and Compartmental Disorders
Keywords: statin-induced myopathy, statins, rhabdomyolysis, myositis, creatine kinase elevation, myalgia, statin withdrawal, adverse drug reactions, cerivastatin, gemfibrozil, drug interactions
MeSH terms: Anticholesteremic Agents, Creatine Kinase, Humans, Muscle Cramp, Muscular Diseases, Myositis, Rhabdomyolysis, Adverse Drug Reaction Reporting Systems, Muscle, Skeletal, Muscle Weakness, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Statin-Associated Myopathy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks